# Generic PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/generic

> The FDA approved generic, sponsored by Vanda Pharmaceuticals Inc. (VNDA), on Dec 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | generic |
| Codes |  |
| Sponsor | Vanda Pharmaceuticals Inc. (VNDA) https://sec-api.dev/companies/vnda/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### Dec 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-14, last confirmed 2025-02-14.
- SEC Form 10-K (accession 0001628280-25-005761): "For HETLIOZ®, the FDA has approved ANDAs for Teva and Apotex, both of which have since launched their generic versions of HETLIOZ® at risk in the U.S. In December 2022, the U.S. District Court for the District of Delaware (Delaware District Court) ruled in favor of Teva and Apotex in our patent litigation relating to their filing of ANDAs for generic versions of HETLIOZ® in the U.S. The Federal Circuit affirmed this ruling, and the U.S. Supreme Court denied our petition for a writ of certiorari in April 2024." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In December 2022, the Company filed patent infringement lawsuits, including Hatch-Waxman Act claims, against each of Teva and Apotex in the U.S. District Court for the District of New Jersey (NJ District Court) asserting that U.S. Patent No. 11,285,129, a method of administration patent that was not litigated in the Delaware District Court cases ('129 Patent), will be infringed by Teva's and Apotex' generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### Mar 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-25, last confirmed 2025-02-25.
- SEC Form 10-K (accession 0001628280-25-007732): "In March 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier." https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm

### Dec 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-14, last confirmed 2026-02-12.
- SEC Form 10-K (accession 0001628280-26-007460): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm
- SEC Form 10-K (accession 0001628280-25-005761): "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex in the Delaware District Court, in each case, asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm

### Jan 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001232524-26-000013): "Furthermore, in January 2026, we received notices from Tris Pharma that it had filed with FDA a Section 505(b)(2) NDA for generic versions of Xyrem and Xywav." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm
- SEC Form 10-K (accession 0001232524-26-000013): "In January 2026, we received notices from Tris Pharma that it had filed with FDA a Section 505(b)(2) NDA for generic versions of Xyrem and Xywav." https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/generic.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Generic PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/generic

```bibtex
@misc{secapidev_pdufa_generic_20261116,
  title        = {Generic PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/generic}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_generic_20261116","title":"Generic PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/generic","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
